That’s a good question. I don’t know if there
Post# of 148238
I’m hoping that once it’s known that leronlimab is effective, whether that be at the next interim or at full enrollment, Yang will be a strong advocate for its widespread use.
Yang has been very careful and guarded in his comments on the efficacy of leronlimab thus far, which is appropriate, but I get the impression that once the trials show meaningful results, he will be fully on board in pushing for an approval.